Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2016 | Targeting RAS oncogenes in patients with NRAS-mutated melanoma

Grant McArthur, MBBS, BMedSci, PhD, FRACP from the Peter MacCallum Cancer Centre, Melbourne, Australia gives an overview of mutations in melanoma and developments in therapies to combat such mutations. 70-80% of melanoma cases have activating mutations in BRAF MEK/ERK pathway. 40-50% have mutations in BRAF and 15-20% have mutations in NRAS. Prof. Grant McArthur explains the first positive Phase III trial called NEMO of binimetinib targeting the RAS oncogene in patients with NRAS-mutated melanoma (NCT01763164). Meaningful improvements in progression-free survival (PFS) have been seen and Prof. McArthur finds this promising for the future. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.